CN121013727A - 用于治疗具有a型血友病的对象的结合活化凝血因子ix和凝血因子x的双特异性抗体与凝血因子x的并用 - Google Patents

用于治疗具有a型血友病的对象的结合活化凝血因子ix和凝血因子x的双特异性抗体与凝血因子x的并用

Info

Publication number
CN121013727A
CN121013727A CN202480027809.5A CN202480027809A CN121013727A CN 121013727 A CN121013727 A CN 121013727A CN 202480027809 A CN202480027809 A CN 202480027809A CN 121013727 A CN121013727 A CN 121013727A
Authority
CN
China
Prior art keywords
factor
hemophilia
fixa
bispecific antibody
coagulation factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202480027809.5A
Other languages
English (en)
Chinese (zh)
Inventor
野上惠嗣
中岛由翔
清水一贵
高见英辅
中野宏俊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Nara Medical University PUC
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Nara Medical University PUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken, Nara Medical University PUC filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Publication of CN121013727A publication Critical patent/CN121013727A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202480027809.5A 2023-04-28 2024-04-26 用于治疗具有a型血友病的对象的结合活化凝血因子ix和凝血因子x的双特异性抗体与凝血因子x的并用 Pending CN121013727A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023-074020 2023-04-28
JP2023074020 2023-04-28
PCT/JP2024/016461 WO2024225440A1 (ja) 2023-04-28 2024-04-26 血友病ａを有する対象の処置のための、活性化凝固第ｉｘ因子及び凝固第ｘ因子と結合する二重特異性抗体と血液凝固第ｘ因子の併用

Publications (1)

Publication Number Publication Date
CN121013727A true CN121013727A (zh) 2025-11-25

Family

ID=93256843

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202480027809.5A Pending CN121013727A (zh) 2023-04-28 2024-04-26 用于治疗具有a型血友病的对象的结合活化凝血因子ix和凝血因子x的双特异性抗体与凝血因子x的并用

Country Status (6)

Country Link
EP (1) EP4702987A1 (https=)
JP (1) JPWO2024225440A1 (https=)
KR (1) KR20250174932A (https=)
CN (1) CN121013727A (https=)
AU (1) AU2024263657A1 (https=)
WO (1) WO2024225440A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
JP6698102B2 (ja) * 2015-04-17 2020-05-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 凝固因子と多重特異的抗体を用いた併用療法

Also Published As

Publication number Publication date
JPWO2024225440A1 (https=) 2024-10-31
KR20250174932A (ko) 2025-12-15
WO2024225440A1 (ja) 2024-10-31
AU2024263657A1 (en) 2025-11-13
EP4702987A1 (en) 2026-03-04

Similar Documents

Publication Publication Date Title
US9090697B2 (en) Methods for treating bleeding disorders
Mancuso et al. Benefits and risks of non‐factor therapies: Redefining haemophilia treatment goals in the era of new technologies
EP2164978A1 (en) Compositions and methods for modulation of adamts13 activity
KR20190052027A (ko) 응고 인자 결합 단백질 및 이의 용도
Schultz et al. The effect of emicizumab and bypassing agents in patients with hemophilia–an in vitro study
JP2013531651A (ja) 線溶亢進を伴う凝固障害の処置
Peyvandi et al. Exploring nonreplacement therapies’ impact on hemophilia and other rare bleeding disorders
US10676539B2 (en) Tissue plasminogen activator antibodies and methods of use
Yamaguchi et al. In vitro validation of chromogenic substrate assay for evaluation of surrogate FVIII-activity of emicizumab
Diness et al. Recombinant human factor VIIa (rFVIIa) in a rabbit stasis model
CA2934081A1 (en) Fusion proteins comprising factor ix for prophylactic treatment of hemophilia and methods thereof
Sefiane et al. Differences in venous clot structures between hemophilic mice treated with emicizumab versus factor VIII or factor VIIIFc
Keshava et al. Therapeutic doses of recombinant factor VIIa in hemophilia generates thrombin in platelet‐dependent and‐independent mechanisms
Proulle et al. Injection of recombinant activated factor VII can induce transient increase in circulating procoagulant microparticles
CN121013727A (zh) 用于治疗具有a型血友病的对象的结合活化凝血因子ix和凝血因子x的双特异性抗体与凝血因子x的并用
CN106413744B (zh) 用于在出血性疾病治疗中改善止血的人凝血酶原和活化的因子x的组合物
Ogiwara et al. Insights from in vitro global assays on possible doses of concomitant hemostatic agents in the presence of NXT007 in hemophilia A
Schuepbach et al. Lepirudin therapy for thrombotic complications in congenital afibrinogenaemia
Tiede et al. Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa)
Lingamaiah et al. Emicizumab: An FDA-Approved Monoclonal Antibody in the Treatment of Hemophilia A
EP4539885A1 (en) Activators of coagulation factor x and formulations thereof for treating bleeding disorders
EP4473008A2 (en) Compositions and methods for treating factor ix deficiency
Woods et al. Coagulation concentrates for inherited bleeding disorders
US20040198660A1 (en) Tissue factor antagonist and protein C polypeptide compositions
Fehr et al. The influence of bevacizumab on platelet function

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination